Search for a command to run...
Incretin hormones were initially recognized for their ability to amplify insulin secretion in response to rising postprandial glucose levels. However, their biological significance is now understood to extend far beyond this classical incretin effect, encompassing broader roles in the regulation of glucose metabolism and energy balance. At the same time, the glucose-dependent insulinotropic actions of incretins have served as the principal foundation for the development of incretin-based therapies, which have become central to modern diabetes treatment and now extend beyond classical Glucagon-like peptide-1 (GLP-1) receptor agonists to include newer agents, such as dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists. Yet, as this therapeutic class continues to expand, important questions remain regarding the intracellular architecture that determines incretin responsiveness. Within β-cells, c-jun N-terminal kinase (JNK) signaling has classically been discussed in the context of stress responses, inflammation, and apoptosis under pathophysiological conditions associated with diabetes. In this setting, JNK activation has often been linked to β-cell dysfunction and loss of functional β-cell mass. At the same time, however, the role of individual JNK isoforms is likely to be more nuanced than a uniformly deleterious model would suggest1. This broader context makes it particularly interesting to ask whether specific JNK family members may also participate in preserving β-cell signaling competence under metabolic or inflammatory stress. In the current study, Louzada et al. identify JNK3 as an important intracellular determinant of β-cell incretin responsiveness2. Using β-cell-specific JNK3 knockout mice together with complementary experiments in human islets, they demonstrate that loss of JNK3 impairs glucose tolerance and insulin secretion, particularly after oral glucose or nutrient challenge, while also reducing GLP-1 receptor expression and attenuating the cytoprotective actions of GLP-1 receptor activation (Figure 1). These findings position JNK3 not merely as a stress-related kinase, but as a key regulator of the intracellular signaling competence required for incretin action. Incretin responsiveness should not be viewed as a simple linear output of canonical cyclic adenosine monophosphate (cAMP)-mediated signal amplification. Rather, it emerges from a finely regulated intracellular signaling network within the β-cell. Incretin action has classically been explained through canonical Gs-dependent cAMP generation. However, downstream responses have been shaped by broader signaling crosstalk, receptor trafficking, and context-dependent pathway engagement. In GLP-1 biology, β-cell signaling has increasingly been understood as context-dependent, with evidence that persistent depolarization or chronic hyperglycemic conditions can shift signaling behavior and alter incretin effectiveness3. In parallel, receptor trafficking and β-arrestin-dependent regulation have emerged as important determinants of signal duration, spatial organization, and downstream outcomes4. In this framework, the present study is important because it identifies JNK3 as an additional intracellular layer that helps preserve GLP-1 receptor expression and signaling competence, thereby fine-tuning how β-cells interpret incretin signals. Another notable strength of the article is that it extends beyond insulin secretion to β-cell survival. In both mouse and human islets, JNK3 loss or inhibition attenuated the ability of exendin-4 to preserve insulin receptor substrate 2 expression and protect against cytokine-induced apoptosis. Similarly, in the multiple low-dose streptozotocin model, GLP-1 receptor agonist-mediated protection5 was only partially retained in the absence of JNK3. This link is noteworthy because the cytoprotective actions of GLP-1 have been mechanistically connected to cAMP response element-binding protein-dependent survival signaling and protection against cytokine-induced β-cell apoptosis, and the present study places JNK3 within this framework. Thus, the present study connects incretin signaling to intracellular pathways more commonly discussed in the context of stress, inflammation, and cell fate regulation, helping bridge two views of GLP-1 biology: one centered on acute insulin secretory amplification, and the other on cytoprotective signaling that preserves β-cell integrity under metabolic or inflammatory stress. At the same time, the study raises several important questions. Most functional experiments were performed with exendin-4, so it remains uncertain how broadly these findings apply across currently used GLP-1 receptor agonists with distinct trafficking and signaling profiles. It is also not yet clear whether a comparable JNK3-dependent regulatory layer exists for GIP receptor signaling, or whether the intracellular logic differs between incretin receptors. Given the tissue distribution of JNK3, it will also be of interest to determine whether the relevance of JNK3 extends beyond the β-cell. JNK3 is expressed predominantly in the brain, and central GLP-1 signaling is now recognized as an important regulator of feeding behavior and glucose metabolism. Although direct evidence is currently lacking, it is tempting to speculate that JNK3 may also contribute to the fine-tuning of nutrient-related signaling in GLP-1-responsive neural circuits. Overall, Louzada et al. identify JNK3 as a previously underappreciated regulator of β-cell incretin responsiveness2. The central insight is that JNK3 helps preserve the intracellular state required for effective incretin signaling. Understanding this fine-tuning process will likely be essential for interpreting variable therapeutic responses and for designing the next generation of incretin-based strategies. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.